Global Medical Foods for Inborn Errors of Metabolism Market – Industry Trends and Forecast to 2031

Medical Foods for Inborn Errors of Metabolism Market Analysis and Size

A rise in the number of incidences of Inborn Errors of Metabolism (IEM) and the preference for dietary supplements over Enzyme Replacement Therapy (ERT) are expected to drive the market growth. The lack of reimbursement facilities for these medical foods and also their high cost, potentially restraining the market growth.

Data Bridge Market Research analyzes that the global medical foods for inborn errors of metabolism market is expected to grow with a CAGR of 14.1% in forecast period of 2023 to 2031 and is expected to reach USD 7,998.77 million by 2031 from USD 2,477.81 million in 2023.

The global medical foods for inborn errors of metabolism market report provides details of market share, new developments, and the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, products approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal.

Market Definition

Inborn Errors of Metabolism (IEM) are a group of disorders in which the body fails to convert food into energy. Due to mutations in genes, there is less or no production of specific enzymes, these enzymes are responsible for breaking down certain substances. This breakdown leads to the accumulation of some toxic substances and results in severe complications. To treat these disorders, the concerned patients are given specific diets which are also known as medical foods under the supervision of physicians. For instance, Phenylketonuria (PKU) is a disease in which there is an accumulation of an amino acid which is known as phenylalanine. This can cause intellectual disability, seizures, and many other mental disorders. To treat this, they are given IEM diets such as Phenylketonuria (PKU)-1 manufactured by Pristine Organics Pvt Ltd.

Global Medical Foods for Inborn Errors of Metabolism Market Dynamics

Drivers

• Rising Incidences of Inborn Errors of Metabolism (IEM)

Advanced diagnostic methods play an essential role in the increasing acceptance of IEM. In the past, these disorders were often misdiagnosed or overlooked due to limited information and diagnostic tools. However, advances in medical technology and genetic testing have changed our ability to accurately diagnose IEM. Advanced technologies such as next-generation sequencing and biochemical analysis allow healthcare professionals to identify specific genetic mutations or abnormalities in metabolic pathways associated with these disorders. This improved diagnostic accuracy has contributed to the increased incidence of IEM. For instance, advances in next-generation sequencing technology have made it possible to identify rare IEM variants that were previously difficult to locate. This enabled a more accurate and comprehensive diagnosis of these disorders.

• Rising Preference for Dietary Supplements Over Enzyme Replacement Therapy (ERT)

The rising preference for dietary supplements over Enzyme Replacement Therapy (ERT) in the treatment of IEM may be due to several factors. First, dietary supplements offer a non-invasive and convenient approach to treatment. Unlike ERT, which often involves an injection or infusion, supplements can be taken orally, making them more attractive to patients who want a less invasive option. In addition, food supplements provide comprehensive nutritional support, as they contain various nutrients, cofactors, and substrates necessary for optimal metabolism. This broader spectrum of support addresses several metabolic deficits associated with specific IEM, which can lead to more effective management of the condition.

The increased popularity of nutritional supplements has led to a growing demand for specialty medical foods that meet the unique nutritional needs of IEM patients. This expanded the size of the market and led manufacturers to develop a wider range of products to meet this demand. In addition, the preference for dietary supplements encouraged R&D to improve the composition and effectiveness of medical foods, which led to the use of new and better alternatives. Thus, the rising preference for dietary supplements over ERT in the management of IEM is expected to drive market growth.

Opportunities

• Government Initiatives and Programs for Creating Awareness About Inborn Errors of Metabolism

Governments around the world have recognized the importance of raising awareness about IEM and have implemented various initiatives and programs to address this need. These initiatives aim to educate healthcare professionals, individuals and families affected by IEM, and the general public. Here are some government initiatives and programs to raise awareness of IEM. Government initiatives and programs aimed at increasing awareness of IEM act as market opportunities, driving demand for diagnostic tools, therapeutic procedures, and specialty products. These initiatives also promote R&D, facilitate market expansion through international collaboration and provide funding and support to companies in the field. Thus, government initiative and programs for creating awareness about IEM is expected to provide an opportunity for market growth.

Restraint/Challenge

• High Cost of Medical Foods

The high cost of medical foods is due to many factors that affect the cost of their production, development, and distribution. Firstly, special medical foods require extensive R&D. Manufacturers invest in scientific research and clinical trials to find the optimal combination of nutrients, bioactive compounds, and therapeutic agents to treat specific health conditions. This study involves the expertise of nutritionist’s food and health professionals, which increases the total cost. The high cost of medical foods is a market constraint because it limits affordability and market reach. Expensive price tags put these specialty nutritional products out of reach for many people. Thus, the high cost of medical foods is expected to restraint market growth.

Recent Developments

• In October 2023, Nestlé Health Science and Amwell announced a collaboration to help health organizations improve patients’ overall health through innovative digital solutions focused on nutrition. Together the companies are developing a portfolio of novel solutions to help improve clinical and financial outcomes. This will enhance the brand image for both the companies
• In March 2021, Meiji Co., Ltd. launched formula milk in tablet format under Danone's Aptamil brand in the UK. The tablets, featuring pre-measured tabs, aim to provide convenience for parents. Production began in Wexford, Ireland, combining Meiji's technology with Danone's recipes. Danone plans to expand the product to other European countries starting in 2022. Meiji aims to increase overseas sales to 10% by FY 2026

Global Medical Foods for Inborn Errors of Metabolism Market Scope

The global medical foods for inborn errors of metabolism market is segmented into six notable segments based on products, diseases, age group, forms, packaging, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Products

• Amino Acid
• Low Protein Food
• Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
• Low-Calcium/Vitamin D-Free Infant Formula with Iron
• Others

On the basis of products, the global medical foods for inborn errors of metabolism market is segmented into amino acid, glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein food, and others. 

Diseases

• Phenylketonuria (PKU)
• Tyrosinemia Types I and II
• Maple Syrup Urine Disease (MSUD)
• Homocystinuria
• Glutaric Acidemia Type I
• Urea Cycle Disorders
• Methylmalonic Acidemia
• Isovaleric Acidemia
• Organic Acidurias
• Renal Disease
• Propionic Acidemia
• Disorders of Leucine Metabolism
• Others

On the basis of diseases, the global medical foods for inborn errors of metabolism market is segmented into Phenylketonuria (PKU), tyrosinemia types I and II, Maple Syrup Urine Disease (MSUD), homocystinuria, glutaric acidemia type I, urea cycle disorders, methylmalonic acidemia, isovaleric acidemia, organic acidurias, renal disease, propionic academia, disorders of leucine metabolism, and others.

Age Group

• Infants
• Weanings
• Adolescent
• Adults

On the basis of age group, the global medical foods for inborn errors of metabolism market is segmented into infants, weaning, adolescent, and adults.

Forms

• Powder
• Liquid
• Tablets
• Gels
• Others

On the basis of forms, the global medical foods for inborn errors of metabolism market is segmented into powder, liquid, tablets, gels, and others.

Packaging

• Can
• Packets
• Bottle
• Jar
• Others

On the basis of packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packets, bottle, and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores
• Online Pharmacy
• Others

On the basis of distribution channel, the global medical foods for inborn errors of metabolism market is segmented into retail pharmacy, hospital pharmacy, online pharmacy, drugs store, and others.

Global Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights

The global medical foods for inborn errors of metabolism market is segmented into six notable segments based on products, diseases, age group, forms, packaging, and distribution channel.

The countries in the global medical foods for inborn errors of metabolism market are, U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Finland, Denmark, Sweden, Norway, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, New Zealand, Vietnam, Philippines, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Qatar, Egypt, Oman, and rest of Middle East and Africa.

North America is expected to dominate the global medical foods for inborn errors of metabolism market due to its cutting-edge healthcare infrastructure, intensive research endeavors, stringent regulatory oversight, heightened public awareness about these conditions, widespread access to comprehensive insurance coverage, and proactive governmental policies. U.S. is expected to dominate the North America region due to the manufacturers providing innovative solutions for managing rare genetic disorders and hence, the revenue is highly generated in this region. China is expected to dominate the Asia-Pacific region due to its competitive advantage in production efficiency and cost-effectiveness. Germany is expected to dominate the Europe region as many improved and advanced products are being launched in this market by the manufacturers.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data point downstream and upstream value chain analysis, technical trends porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Medical Foods for Inborn Errors of Metabolism Market Share Analysis

Global medical foods for inborn errors of metabolism market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the global medical foods for inborn errors of metabolism market.

Some of the prominent participants operating in the global medical foods for inborn errors of metabolism market are Nutricia, Abbott, Baxter, Nestlé Health Science, Meiji Holdings Co., Ltd., Hexagon Nutrition Ltd, Kate Farms, Primus Pharmaceuticals, inc., Promin, Ajinomoto Cambrooke, Inc., Galen Limited, Piam Farmaceutici S.P.A., Orpharma Pty Ltd., PKU-Mdmil.com, B. Braun SE, Pristine Organics Pvt Ltd., Mead Johnson & Company, LLC., EBM Medical, Biovencer Healthcare Pvt Ltd, and Solace Nutrition, among others.

SKU-53800